Cite
HARVARD Citation
Gehin, J. et al. (n.d.). SAT0261 Certolizumab pegol serum levels ≥20 mg/l are associated with treatment response in patients with axial spondyloarthritis. data from the nor-dmard study. Annals of the rheumatic diseases. p. 994. [Online].